Search

Displaying results 961 - 970 of 8515 in total
  1. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].

  2. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor … [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]

  3. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]

  4. Drug

    Epirubicin

    go.drugbank.com/drugs/DB00445
    ApprovedInvestigational

    An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

  5. Drug

    Palonosetron

    go.drugbank.com/drugs/DB00377
    ApprovedInvestigational

    As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

    Synonyms: (3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one
  6. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin … More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B

  7. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  8. Drug

    Olive oil

    go.drugbank.com/drugs/DB09567
    ApprovedInvestigational

    Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].

  9. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

  10. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular